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Abstract The small alkylating molecule, 3-bromopyruvate
(3BP), is a potent and specific anticancer agent. 3BP is differ-
ent in its action from most currently available chemo-drugs.
Thus, 3BP targets cancer cells’ energy metabolism, both its
high glycolysis (“Warburg Effect”) and mitochondrial oxida-
tive phosphorylation. This inhibits/ blocks total energy pro-
duction leading to a depletion of energy reserves. Moreover,
3BP as an “Energy Blocker”, is very rapid in killing such cells.
This is in sharp contrast to most commonly used anticancer
agents that usually take longer to show a noticeable effect. In
addition, 3BP at its effective concentrations that kill cancer
cells has little or no effect on normal cells. Therefore, 3BP can
be considered a member, perhaps one of the first, of a new
class of anticancer agents. Following 3BP’s discovery as a
novel anticancer agent in vitro in the Year 2000 (Published in
Ko et al. Can Lett 173:83–91, 2001), and also as a highly
effective and rapid anticancer agent in vivo shortly thereafter
(Ko et al. Biochem Biophys Res Commun 324:269–275,
2004), its efficacy as a potent anticancer agent in humans
was demonstrated. Here, based on translational research, we
report results of a case study in a young adult cancer patient
with fibrolamellar hepatocellular carcinoma. Thus, a bench
side discovery in the Department of Biological Chemistry at
Johns Hopkins University, School of Medicine was taken
effectively to bedside treatment at Johann Wolfgang Goethe
University Frankfurt/Main Hospital, Germany. The results
obtained hold promise for 3BP as a future cancer therapeutic
without apparent cyto-toxicity when formulated properly.
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Introduction
As depicted in Fig. 1, the alkylating agent 3BP covalently
pyruvylates certain proteins generally at cysteine residues.
The pyruvylated proteins, e.g., isocitrate lyase (Ko and
McFadden 1990) and an aldolase (Meloche and Monti
1967) often lose their biological activity. The “hands on”
discovery by coauthor YHK in the year 2000 of 3BP as a
potent and specific anticancer agent, published in 2001 (Ko
et al. 2001), was based on results of much previous work on
cancer metabolism in the laboratory of the corresponding
author (PLP) (Reviewed in Pedersen 1978; Pedersen 2007a;
Pedersen 2007b; Mathupala et al. 2009; Mathupala et al.
2010 ), and on YHK’s prior graduate (M.S., Ph.D.) work in
enzymology at Washington State University (Ko and
McFadden 1990; Abeysinghe et al. 1991).
Assigned by coauthor PLP the role of identifying (dis-
covering) an anticancer agent specifically targeted at energy
metabolism, YHK knew that the essential criteria for success
(Pedersen 2007a) were to find an agent that 1) leaves normal
cells intact while 2) inhibiting both the most common bio-
chemical phenotype of cancer cells, i.e., the “Warburg Effect”,
elevated glycolysis even in the presence of oxygen (Warburg
1956), and also mitochondrial ATP production. Then, both
energy (ATP) production factories (mitochondria and
glycolysis) of the cancer cells would be destroyed and normal
cells would remain intact. After an extensive study of the
literature, YHK selected only a few candidate compounds
(<20) for the initial screen, and of these showed that only
one, i.e., 3-bromopyruvate (3BP), met the two criteria noted
above (Ko et al. 2001). Later YHK would lead a team of
investigators in an effort to test 3BP’s capacity to cure rats
bearing large solid tumors. Significantly and surprisingly, all
the treated animals were cured, i.e., all tumors were eradicated
(Ko et al. 2004). Moreover, eradication occurred quickly
(<1 month). Thereafter, the animals lived out a normal life
without return of cancer (Ko et al. 2004).
Significantly, 3BP as an “Energy Blocker” specific for
cancer cells that exhibit a “Warburg Effect” is quite different
in its action from most currently available chemo-drugs that
frequently target either some aspect of nucleic acid metab-
olism or signal transduction pathways. Rather, 3BP, as noted
above, targets a cancer cell’s energy metabolism, i.e., both
glycolysis and mitochondrial oxidative phosphorylation (Ko
et al. 2001). This inhibits total energy (ATP) production and
depletes all energy reserves. This happens quickly (within
minutes) and with little or no effect on most normal cells or
the animals. In contrast, most commonly used anticancer
agents take a longer period of time (weeks/months) to show
a noticeable effect. Therefore, 3BP as a small molecule and
covalent drug, is a very potent, rapid and quite specific
anticancer agent (Reviewed in Mathupala et al. 2009, 2010).
Interestingly, and only very recently it was reported that
many pipeline cancer drugs under study by major pharmaceu-
tical companies are minimally effective (Jarvis 2011). There-
fore, these companies are urgently looking for novel
candidates to combine with their pipeline drug(s). In contrast
to 3BP that targets cancer cells’ energy production factories
(Ko et al. 2001), many of these pipeline drugs are based on
targeting mTOR/ PI3K in cell signaling pathways (Jarvis
2011). Thus, the focus on signal transduction pathways for
anticancer drug discovery may be waning. In addition, it was
also reported (Guterman 2011) that a growing group of
researchers from both academe and companies have initiated
searches for covalent drug candidates. Clearly, the small mol-
ecule 3BP meets this specification as a promising anticancer
agent as it is in fact a small molecule and it does bind
covalently with efficacy and specificity to the active sites of
certain enzymes (Staub and Denes 1967; Meloche and Monti
1967; Ko and McFadden 1990; Ko et al. 2001).
Significantly, much earlier work from the corresponding
author’s laboratory (Bustamante and Pedersen 1977)
reported that the “Warburg Effect” common to most cancers
is due in large part to their overexpression of hexokinase 2
(HK2) that binds to the outer mitochondrial membrane. This
likely helped lead in part to the most common imaging
technique used today to detect cancer throughout the world,
i.e., positron emission tomography (PET). Significantly,
Fig. 1 Pyruvylation of Proteins with a Novel Small Anticancer Agent,
3-Bromopyruvate (3BP). 3BP, a small alkylating agent, pyruvylates
proteins by releasing bromide ion (covalent modification). In general,
the pyruvylation site on proteins is cysteine. Pyruvylated proteins often
lose their biological functions resulting in cancer cell death. At the
bottom of the reaction scheme, a space filling model of 3BP is reflected
on the mirror as a skeletal formula structure (BrCH2-CO-COO
-)
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detection of cancer by PET imaging is based on overexpres-
sion of mitochondrial bound HK2 (Fig. 2a). In this imaging
method a labelled glucose analogue, 2-18fluoro-2-deoxy
glucose (18FDG), is phosphorylated by HK2 at the 6th
carbon with ATP to become 2-18fluoro-2-deoxy glucose 6-
phosphate (18FDG-6-P). Such labelled FDG compounds
were first developed by Ido and colleagues (Ido et al.
1978). Significantly, 18FDG-6-P is metabolically inactive
and not further metabolized. Thus, its accumulation is
detected by the PET scanning imaging and helps locate
metabolically active (highly glycolytic) cancers.
Hence, it is suggested that PET scan positive cancer types
may be benefited after treatment with a patented and pro-
prietary formulation of 3BP. It is worth noting that unfor-
mulated 3BP may be harmful in some cases.
A case report
Herein, we present a 16-year-old Caucasian male with a
palpable mass over the right upper quadrant of the abdomen.
This patient was initially presented to the emergency
Fig. 2 Diagnosis of Cancer
after Detection by PET
Imaging. a Detection of cancer
by Positron Emission
Tomography (PET) imaging is
based on highly overexpressed
Hexokinase 2 (HK2) in cancers.
PET imaging is used widely to
detect cancers which consume
glucose avidly. A glucose
analogue, 2-fluoro-2-deoxy
glucose (18FDG), is phosphor-
ylated by hexokinase 2 at the
6th carbon with ATP to become
2-fluoro-2-deoxy glucose 6-
phosphate (18FDG-6-P). Accu-
mulation of the metabolically
inactive 18FDG-6-P is detected
by PET scanning imaging de-
vice and helps locate metaboli-
cally active cancers in the body.
b–g Confirmation of presence
of metabolically active cancers
in the patient’s liver, bile duct,
and lymph nodes based on PET
scan imaging. Descending
transverse axial plane views of
the patient’s liver are shown af-
ter PET imaging (b–g). Abbre-
viations are: RL (right liver
lobe), LL (left liver lobe), and K
(kidneys). The highly metabol-
ically active areas are indicated
by blue arrows with numbers in
c, d, and e 1 (bile duct area), 2–
5 (lymph nodes). In addition,
there are highly active focal
regions in the right liver lobe as
shown in f. The trace 18FDG is
eliminated through the kidneys
as evidenced by bright spots
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department of the Jeroen Bosch hospital in den Bosch, the
Netherlands. His presenting symptom was abdominal pain
localized to the spleen. His body temperature was 34.6°C at
first presentation and his blood chemistry revealed high values
of the liver enzymes alanine transaminase (ALT), aspartate
transaminase (AST), and gamma glutamyl transpeptidase
(GGT), indicating liver abnormality / damage. He was
hospitalized immediately and evaluated by Computed To-
mography (CT), Magnetic Resonance Imaging (MRI), liver
biopsy, echo imaging, and PET scanning. The PET scan
suggested that the patient had very diffuse and metabolically
active tumors in his liver (Fig. 2b and g). Indeed, all tests
indicated primary liver cancer of the fibrolamellar carcinoma
form (FLC). A second opinion was requested and provided by
Fig. 3 Monitoring Blood
Ammonia, Nausea, Uric Acid,
and Urea during 3BP
Treatments. a Blood Ammonia
Levels (Left Axis) and Nausea
(Right Axis) during 3BP
Treatments. Each 3BP
treatment is indicated at the top
of the graph in red arrows and
numbers. Nausea was
determined as the number of
vomiting episodes per week
during the entire treatment
period and is depicted in the
blue graph. The greatest
number of nauseous episodes
was observed after the third
treatment. This coincided with
the patient’s increased ill
feeling. Similar spikes were
noted directly following
treatment 5 and 6, but with
rapid recovery. These nauseous
episodes gradually decreased,
and the patient felt much better
after about 20 weeks. Blood
ammonia levels are indicated in
the green graph. Interestingly,
an increase of blood ammonia
levels followed the second,
third and fourth treatments and
correlated with an increase in
nauseous episodes. Then, blood
ammonia levels and nauseous
episodes began decreasing
following subsequent 3BP
treatments. b Comparison of
Ammonia Levels with Urea and
Uric acid Levels in Blood.
Ammonia levels (green, left
axis) were compared with both
urea (pink, right axis) and uric
acid (purple, right axis) levels
in blood as a function of 3BP
treatment time line. Note that
during 3BP treatment ammonia
levels fluctuated more than
those of urea and uric acid
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the Erasmus Medical Centre in Rotterdam, the Netherlands. It
was confirmed that the abdominal pain was caused by a spleen
infarct, induced by the pressure of the tumor on the blood
vessels supplying the spleen. This resulted in splenic enlarge-
ment (Fig 4a and 4c) and some necrosis (Data not shown). The
patient had no history of hepatitis and no positive tests for
hepatitis.
There is no known treatment for FLC except transplan-
tation, and the patient did not fulfill the requirements for this
process due to the presence of tumor in the choleductus and
spinal lymph nodes. Right after the diagnosis, Sorafenib had
been approved for primary HCC patients as an orphan drug.
Treatment with Sorafenib was started, varying the doses from
200, 400, to 800 mg/day. However, due to lack of experience
with such young patients, the treatment outcome was carefully
monitored and stopped according to the manufacturer’s in-
struction when ALT and /or AST values exceeded the tolera-
ble values. Initial results with Sorafenib were encouraging.
Thus, tumor growth appeared to have halted during the first
2 months of Sorafenib application, even with some regression
of tumor volume. However, after 6 months, CTscans indicated
a renewed expansion of the tumor’s mass, and Sorafenib
treatment was halted. By now, the health condition of the
patient had deteriorated, in fact, so far that he could not
consume sufficient amounts of food to sustain life. On the
basis of this condition, a duodenal feeding tube was installed
and continuous (24 h) enteral feeding was started. The caloric
intake was adjusted to 2000–3000 kCalories per day.
While the patient’s health was deteriorating, a contact
was established with research scientists (coauthors PLP
and YHK) at the John’s Hopkins University, School of
Medicine (Year 2008) to learn about their promising experi-
mental anticancer agent, 3BP. Other contacts were also made
with TJV (coauthor) at the University of Frankfurt for the
application of 3BP by a Transcatheter Arterial ChemoEmbo-
lization (TACE) delivery method. Permission was obtained
from the Ethics committee of the University of Frankfurt for
the use of 3BP on this young male patient with FLC. The
Fig. 4 Comparison of the CT images of the patient’s abdominal area
before and after 3BP Treatment. Selected pairs of transverse axial CT
scans at identical positions in the abdomen immediately after treatment
with two cytostatics (left images, considered as “before 3BP treat-
ment”) and after the 9th treatment of 3BP (right images): In a Lipio-
dol® accumulations are indicated by black asterisks. They are
dispersed throughout all sections of the liver (L), especially in the right
lobe, indicating excellent localization and containment. Enlarged para-
mesenteric and coeliac lymph nodes are visualized in c, right under the
green asterisk. The spleen (S) was enlarged due to complete blocking
of the portal vein by a thrombus. This blocking was compensated by
formation of several arterial shunts (not presented in these images).
After the 9th 3BP treatment, the images on the right were obtained. No
Lipiodol® was used during 3BP treatment and subsequently no such
signals are present in these images. Tumors had become necrotic (b
and d) and encapsulated and showed fibrosis. Lymph nodes appeared
stable in size and shape. The spleen size was drastically reduced. The
ascites marked as “1” was evident before and after treatment. The blue
arrow indicates the feeding tube present before 3BP treatment. After
3BP treatment, the patient was able to consume much more food and
the feeding tube became unnecessary and removed
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patient’s parents signed the necessary form of consent and the
patient himself agreed to the treatment.
While waiting for the permission from the Ethics Com-
mission and in view of his severe situation, it was decided
that it would be essential to treat the patient as soon as
possible with the currently approved cytostatics by TACE
in order to halt the rapidly progressing tumor. Then, the first
TACE was performed with Gemcitabine and Cisplatin on
January 26, 2009. After delivery of these cytostatics, the blood
vessels were blocked temporarily by EmboCept®. Then, the
tumor locations were viewed immediately by infusion of
Lipiodol® followed by a CT scan. Due to cyto-toxicity, this
was the first and last use of these two chemo-drugs. Likewise,
the use of Lipiodol® was not continued during 3BP treatment
due to a possible interaction between Lipiodol® and 3BP. One
month later, permission from the Ethics committee was
obtained. The patient was treated immediately via TACE with
specially formulated 3BP (patented and proprietary) twice on
the first day of treatment (February 26, 2009), a total dose
250 mg. More clearly, the delivery was bolus, meaning a rapid
push of the entire dose into the artery over just a few minutes.
Therefore, the 3BP delivery can be called a ‘Transcatheter
Intra-Arterial Bolus Injection’ followed by a brief emboliza-
tion with EmboCept®. The patient did not experience any
discomfort during the first treatment with 3BP. The only
discomfort was caused by the fact that the second infusion
took place one hour after the first, and the local anesthetic was
becoming less effective. No other adverse effects were noted
during the normal 4 h recovery period and the patient left the
hospital at 6:00 pm. The patient felt very hungry and wished to
go to dinner. It appeared that the treatment may have increased
the patient’s appetite. This was an initial sign and hope for
relying less on the enteral feeding tube. Indeed, the 3BP
treatment helped the patient consume sufficient calories.
Due to a large tumor burden at the presentation, it was
determined to try to obtain a very high dosing with 3BP in
the first treatment month. A second treatment was scheduled
2 weeks after the first, the third after 4 weeks. After the
second application (128 mg), which went without any acute
problems, the patient started to get disturbed. Four days
later, the patient went into a hepatic coma and was hospi-
talized. Blood chemistry revealed an elevated level of AST
and ALT, but not far beyond his usual levels. On the other
hand, the blood ammonia level was about 120 μM (Fig. 3a
and b, green graph), more than the maximum physiological
levels for adults and children, 21–50 μM and 41–80 μM,
respectively. The urea level was low (Fig. 3b, pink graph),
an average of 5 mM, indicating a still functioning nitrogen
detoxification of the liver and kidneys. Similarly, the blood
uric acid remained constant at about 0.2 mM as depicted in
Fig. 3b, purple graph. The normal ranges for blood urea
nitrogen and uric acid are 2.1–7.1 mM and 0.2–0.5 mM,
respectively.
The diagnosis was hepatic coma, which usually results in
death. It was suspected that the patient was undergoing a
potential tumor lysis syndrome (TLS) after three 3BP treat-
ments. Without additional help from the hospital, the patient
was allowed to leave the hospital by ambulance and trans-
ferred back home. After 4 h at home, he began to show signs
of recovery, and by nightfall, he was completely back to
baseline, with most of his mental capabilities functioning.
The recovery continued over the next day. The patient
was able to consume food and have social interactions with
his friends, without any memory of the comatic phase.
The treatment team, in close communication with the
patient and his parents, and with their consent, decided to
continue with the 3BP treatment as scheduled, with modifi-
cations in which the blood chemistry was carefully moni-
tored. Especially, ammonia, urea, and potassium were added
to the weekly schedule for monitoring. A medication for
reducing blood ammonia in liver cancer patients, Hepamerz
was prescribed (6000 mg/day) and used for the patient as
needed, but always following application of 3BP.
Elevations of the patient’s blood ammonia levels (left
axis of Fig. 3a, green graph), were associated with nausea
(right axis of Fig. 3a, blue graph). Urea (pink, right axis of
Fig. 3b), and uric acid (purple, right axis of Fig. 3b) levels
were followed during the entire 3BP treatments.
The ammonia levels following treatment rapidly rose and
gradually went down during the following weeks. The nau-
seous episodes (defined here as “vomiting”) preceded the
rise in blood ammonia levels after each 3BP treatment. The
greatest number of nauseous episodes was observed after
the third treatment. This coincided with the patient’s in-
creased ill feeling. Similar spikes were noted directly fol-
lowing treatments 5 and 6, but with rapid recovery. These
nauseous episodes gradually decreased, and the patient felt
much better after about 140 days (Fig. 3a).
As indicated in Fig. 3b, ammonia levels fluctuated more
than those of urea and uric acid during 3BP treatment. This
is very interesting as FLC is eosinophilic which is indicative
of a higher content of cellular protein than of nucleic acids.
Therefore, it is suggested that the rise in blood ammonia
following 3BP treatment was due to FLC cell death, releas-
ing considerable amounts of cellular proteins. This elevation
of blood ammonia may be characteristic of TLS of FLC as
TLS is generally diagnosed by acute elevations of uric acid,
potassium, and phosphorus in other cancers.
The effective killing of FLC by 3BP was more evident by
comparing the CT images before (Fig. 4a and c) and after
the 9th 3BP treatment (Fig. 4b and d). In Fig. 4a, Lipiodol®
accumulation after TACE is indicated by black asterisks.
They are dispersed throughout all sections of the liver (L),
especially in the right lobe. The CT images depicted in
Fig. 4b and d were obtained in the absence of Lipiodol®.
Hence, these images do not show the bright signals. Pre 3BP
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treatment enlarged paramesenteric and coeliac lymph nodes
are visualized in Fig. 4c, right below the green asterisk. The
pre 3BP treatment spleen (S) in Fig. 4a was enlarged due to
complete blocking of the portal vein by a thrombus, when
compared with the post 3BP treatment size of the spleen in
Fig. 4b. Likewise, the spleen in Fig. 4c (pre-treatment) is
much larger than that of Fig. 4d (post-treatment), document-
ing that the spleen size was drastically reduced after 3BP
treatments. The portal vein thrombosis blockage was com-
pensated by formation of several arterial shunts. Necrotic
areas due to tumor death after 3BP treatment were evident as
shown in Fig. 4b and d, and the tumor areas were encapsu-
lated and showed fibrosis. Lymph nodes were stable in size
and shape. Regeneration of liver tissue was also observed
and the data are being analyzed for future publication.
The ascites as indicated as “1” in Fig. 4b and d were
evident before and after treatment. The blue arrow indicates
the feeding tube present before 3BP treatment. After 3BP
treatment, the patient was able to consume much more food,
so the feeding tube became unnecessary and was removed.
Pre existing ascites and edema continued to be a major
problem for the patient, and despite daily exercise, his
mobility continued to be limited. However, during the sum-
mer of 2009 he started to regain his physical strength and
went out in his wheelchair regularly for a promenade. In
addition, the patient celebrated his 18th birthday at his home
surrounded by many friends and family members on Sep-
tember 9, 2009. The photo of the patient in Fig. 5 was taken
on his birthday.
At the end of October 2009, a part of the discomforting
ascites was removed by CT-guided puncture. About 1 l of
ascites fluid was removed and sent to the pathology lab for
cellular analysis. An outcome of an increased lymphocyte
count with some mesothelial cells, but no malignant cells
was obtained. This lack of tumor cells in the ascites sug-
gested that the tumors in the liver were well encapsulated
and dead. In December 2009 the edema and ascites were
becoming more problematic. Liver functions were over-
loaded due to rapid destruction of the tumor cells resulting
in the liver’s inefficient detoxification. Despite regeneration
of the healthy liver cells, this process apparently could not
compensate adequately for the rapid destruction of tumor
cells and could not detoxify the dead cancer cell debris fast
enough. Consequently, the blood albumin levels were de-
creasing. The patient passed away 2 years after his first
diagnosis due to an overload of liver function.
The patient (Fig. 5) was able to survive a much longer
period than expected with an improved quality of life, which
is clearly attributable to the treatment with 3BP.
Conclusions
1) 3BP is an inhibitor of cancers’ two energy sources, gly-
colysis and oxidative phosphorylation viamitochondria. A
patented and proprietary formulation of 3BP is safe at the
concentrations (2–3.5 mg/kg body weight) employed for
TACE delivery in humans. No major cyto-toxicities of this
specially formulated 3BP have been observed. Please note
that unformulated 3BP may be harmful in some cases.
2) Specially formulated 3BP is efficacious in killing fibro-
lamellar hepatocellular carcinoma (FLC) tumor tissue.
3) Liver regeneration is not inhibited by 3BP treatment.
4) The rate of tumor necrosis due to 3BP treatment seems
to exceed all known cytostatic drugs.
5) Careful monitoring of blood ammonia, uric acid, and
urea levels is paramount during 3BP treatment.
6) The levels of albumin and billirubins are also important
parameters in assessing liver functions and in predicting
a patient’s survival during 3BP treatment.
7) In future clinical trials, earlier stage cancer patients with
a lower tumor burden and positive PET scans may have
Fig. 5 Fighting against immortal cancer cells with immortal spirits of
phoenix, Yvar Verhoeven, and 3-bromopyruvate (3BP). The photo-
graph of the cancer patient (Yvar Verhoeven) in this Case Report was
poised with a novel anticancer agent, 3-bromopyruvate (3BP) and his
favorite legendary immortal bird, phoenix. The picture was taken on
his 18th birthday, September 09, 2009 (09-09-09) at his home in the
Netherlands, after his 7th treatment with 3BP. This was a very special
day as he had been told that he would never make it to his 17th
birthday. In the morning of this special day, the patient’s parents were
awakened with Yvar’s “Happy Birthday” song hummed to himself.
The silver necklace with a silver 3BP molecule as a space filling model
on him was hand-made by his sister. The gold necklace with a copy of
the cartouche of Tut Ankh Amen (rise of the 18th dynasty) was given
to him by a relative of a deceased cancer patient. The immortal
legendary bird, phoenix was very much favored by Yvar and the
phoenix as depicted was tattooed on his upper arm at that time. It
was his personal wish that immortal spirits of phoenix and himself will
help win against the seemingly “immortal” cancer cells. Fight “immor-
tality” of cancer cells with “immortal” spirits and 3BP
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a much better outcome following treatment with spe-
cially formulated 3BP.
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